Abt-122 is a dual variable domain immunoglobulin (DVD-Ig) that targets human TNF and IL-17A, with the potential to treat rheumatoid arthritis (RA). MW: 198.74 KD.

Mas825 is a bispecific antibody targeting both IL-1β and IL-18, effectively modulating the inflammasome cascade in inflammatory diseases. It shows potential for treating patients with COVID-19 and systemic juvenile idiopathic arthritis (sJIA) complicated by macrophage activation syndrome (MAS) and interstitial lung disease (ILD) by reducing pro-inflammatory cytokines and neutrophil counts, thereby improving clinical outcomes. MW: […]

TNB-383B is a fully human bispecific T-cell engager (T-BsAb) monoclonal antibody that targets B-cell maturation antigen (BCMA) and CD3, demonstrating potent anti-tumor activity in patients with relapsed or refractory multiple myeloma (MM). It works by binding to BCMA on malignant plasma cells and CD3 on T cells, facilitating T-cell-mediated lysis of myeloma cells while minimizing […]

Romilkimab is a humanized bispecific immunoglobulin-G4 antibody that targets and neutralizes IL-4 and IL-13, effectively downmodulating the inflammatory response. Its treatment significantly reduces thymus and activation-regulated chemokine (TARC) levels in patients with idiopathic pulmonary fibrosis (IPF) and significantly decreases the modified Rodnan skin score (mRSS) in patients with diffuse cutaneous systemic sclerosis (dcSSc). MW: 198.16 […]

Glofitamab is a T-cell–engaging bispecific antibody that targets CD3 and CD20, demonstrating significant antitumor activity and durable responses in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL). It works by binding to CD20 on B cells and CD3 on T cells, promoting T-cell-mediated lysis of malignant B cells. MW: 170.28 KD.

Istiratumab is a fully human tetravalent bispecific antibody that binds to and co-inhibits IGF-1R and the epidermal growth factor family of receptor tyrosine kinases B3 (ErbB3), with potential anti-tumor activity. MW: 199.64 KD.

Hx009 is a humanized bispecific antibody fusion protein targeting the immunoregulatory checkpoint receptors PD-1 and the human cell surface antigen CD47, with potential immunostimulating, phagocytosis-inducing, and antineoplastic activities. It exhibits anti-tumor effects in patients with advanced malignancies. MW: 173.16 KD.

Tqb2858 is a bifunctional fusion protein consisting of a monoclonal antibody targeting programmed death ligand 1 (PD-L1) fused with the extracellular domain of the transforming growth factor beta (TGF-β) receptor. It simultaneously neutralizes TGF-β on tumor cells and inhibits PD-L1 activity, exhibiting potential antineoplastic and immune checkpoint-modulating effects. MW: 178.22 KD.

Hb0025 is a bispecific antibody that targets PD-L1 and vascular endothelial growth factor (VEGF), with EC50 values of 0.67 nM and 0.48 nM, respectively. It exerts anti-tumor effects by inhibiting VEGF activity and promoting T-cell infiltration into tumors, thereby transforming the immunosuppressive tumor microenvironment into an immune-activated state. MW: 170.8 KD.

Rilvegostomig is a bispecific humanized IgG1 antibody that targets the immunoregulatory receptor programmed cell death protein 1 (PD-1) and the co-inhibitory immune checkpoint molecule T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT). It enhances T-cell activation and promotes a robust anti-tumor immune response, particularly in cancers like non-small cell lung […]